Advanced Biomed (ADVB) vs bioAffinity Technologies (BIAF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Advanced Biomed is the larger company by market cap ($10.1 million vs $6.6 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ADVB | BIAF |
|---|---|---|
| Share price | $6.12 | $5.64 |
| Market cap | $10.11M | $6.58M |
| 1-day change | -2.86% | -8.44% |
| YTD return | +4.79% | — |
| 1-year return | -34.89% | — |
| P/E ratio (TTM) | 1.26 | — |
| EPS (TTM) | $4.85 | $-109.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.23 | $80.70 |
| 52-week low | $3.61 | $4.56 |
| Distance from 52-week high | -74.74% | -93.01% |
| Average volume | 1.75M | 3.67M |
| Shares outstanding | 1.65M | 1.17M |
| Employees | 31 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Healthcare · Diagnostics & Research · 31 employees
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Healthcare · Diagnostics & Research · 57 employees
ADVB vs BIAF FAQ
Which is bigger, Advanced Biomed or bioAffinity Technologies?
Advanced Biomed (ADVB) is larger, with a market capitalization of $10.11M compared with $6.58M for bioAffinity Technologies (BIAF).
Are Advanced Biomed and bioAffinity Technologies in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.